News

Almost 3 years since the beginning of the pandemic, continuous research efforts have begun to paint a better picture of the impact the virus has on the brain and the central nervous system.

The division director of pediatric neurology, and director of the pediatric sleep program at Cohen Children's Medical Center of Northwell Health, spoke about the association between sleep disorders and pediatric epilepsy at the 2022 AES annual meeting. [WATCH TIME: 3 minutes]

The director of the Headache Center at Allegheny Health Network provided perspective on whether focusing in on medications or lifestyle choices has better impacts on improving chronic migraine. [WATCH TIME: 4 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Marwan Sabbagh, MD, FAAN. [LISTEN TIME: 21 minutes]

Findings from a recent randomized study demonstrated effective sleep maintenance of insomnia, as shown by increased sleep time and reduced awakenings, with low concentration of carbon dixoide.

In the largest collected of PML DNA samples, the study identified 4 immune-linked, high effect size, rare variants for use in an iatrogenic PML risk genetic test.

The clinical assistant professor in the division of Sleep Medicine, Department of Neurology, University of Michigan spoke about the associations of mental health with insomnia in transgender youth. [WATCH TIME: 5 minutes]

AOC 1001, an agent consisting of a proprietary monoclonal antibody that binds to the transferrin receptor 1, was safe, tolerable, and showed significant reductions in DMPK, a disease-related mRNA.

The clinical assistant professor in the division of Sleep Medicine, Department of Neurology, University of Michigan, spoke about sleep disorders associated with transgender youths. [WATCH TIME: 4 minutes]

A recent review suggests that children might be affected by specific types of insomnia and that their treatment should be more suitable to their classified insomnia phenotype.

The chief medical officer of Alzheon detailed the efficacy, safety, and potential of ALZ-801, an investigational anti-amyloid therapy being assessed in high-risk individuals with early Alzheimer disease.

In a phase 3 trial, NurOwn failed to meet its primary end point of change on ALSFRS-R; however, the therapy showed significant benefits in those with less severe forms of ALS.

Episode 28 of the AUPN Leadership Minute features Donald S. Higgins, MD, of the VHA; and Gabriele C. De Luca, MD, DPhil, FRCPath, FAAN, of University of Oxford. [WATCH TIME: 5 minutes]

A recent phase 2 study showed a significant decline in wakefulness after sleep onset across both doses of sunobinop for individuals with insomnia recovery from alcohol use disorder.

The professor of medicine at the University of Manitoba discussed the need to change how multiple sclerosis is characterized, and how aging contributes to increased disease progression. [WATCH TIME: 4 minutes]

Bjoern Schelter, MD, Data Analytics and Biostatistics lead at TauRx, provided background on the efficacy, safety, and role of HMTM as a treatment for cognition in pre-Alzheimer disease stages like mild cognitive impairment.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The pediatric epilepsy specialist at Weill Cornell Medicine in New York City spoke on how meetings such as the 2022 AES Conference bring clinicians together as well as how parents motivate them to advance pediatric epilepsy research. [WATCH TIME: 6 minutes]

Howard Fillit, MD, founding executive director of the Alzheimer’s Drug Discovery Foundation, provided perspective on how ADDF and others are advancing the detection and treatment of Alzheimer disease.

The chief executive officer and co-founder of Linus Health provided perspective on the state of clinical trials for Alzheimer disease, and how technology can play a major role in advancing therapeutics going forward. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

High rates of treatment use were observed across all types of spinal muscular atrophy, with nusinersen, the first approved disease-modifying treatment, as the most commonly used.

The assistant professor of neurology at Massachusetts General Hospital and Harvard Medical School spoke about the high risk of epilepsy for the older population at the 2022 AES annual meeting. [WATCH TIME: 1 minute]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and related dementias.

In a recent time-to-event analysis based on two clinical trials of patients with Dravet syndrome results demonstrated an overall reduction in seizure burden with fenfluramine.

Neurology News Network for the week ending December 10, 2022. [WATCH TIME: 4 minutes]

As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased, and in recent years, GFAP has emerged as a valuable candidate to add to the existing panel.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 9, 2022.